<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484210</url>
  </required_header>
  <id_info>
    <org_study_id>2007-FLUSAL-EL-02</org_study_id>
    <secondary_id>2007-006670-29</secondary_id>
    <secondary_id>Sponsor ID</secondary_id>
    <secondary_id>Sponsor FLUSAL-02</secondary_id>
    <nct_id>NCT01484210</nct_id>
  </id_info>
  <brief_title>Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®</brief_title>
  <official_title>Phase III Therapeutic Evaluation Study Comparing the Efficacy and Safety of the Fluticasone/Salmeterol (500/50 μg) Combination Administered With Elpenhaler® (Rolenium®) Versus the Innovative One (Seretide Diskus®) in Patients With Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpen Pharmaceutical Co. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpen Pharmaceutical Co. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish the therapeutic equivalence between the test&#xD;
      (Fluticasone/Salmeterol administered with Elpenhaler®, Rolenium®) and the reference&#xD;
      formulation (Seretide®, administered with Diskus®), both containing 500/50μg of the&#xD;
      Fluticasone/Salmeterol combination.&#xD;
&#xD;
      The study will be conducted in a randomized, double-blind, double-dummy, 2x2 crossover&#xD;
      fashion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In case of inhaled products, it is not possible to follow the classic scheme, based on&#xD;
      similarity of plasma concentration-time behavior of parent drug in assessing bioequivalence.&#xD;
&#xD;
      For this reason, a pharmacodynamic study was designed in order to assess the therapeutic&#xD;
      equivalence of the new formulation of Fluticasone/Salmeterol with the innovative one. The&#xD;
      test and reference Fluticasone/Salmeterol formulations will be compared in terms of their&#xD;
      bronchodilator effects in lung function. Forced Expiratory Volume in 1 second (FEV1) will be&#xD;
      the primary efficacy measure and will be measured in such a way that a similar time-dependent&#xD;
      increase in pulmonary function can be demonstrated for both Fluticasone/Salmeterol&#xD;
      formulations in patients with asthma. In terms of safety comparison, repeated measurements of&#xD;
      adverse events, vital signs, heart rate, blood hematology and biochemistry as well as ECG&#xD;
      changes will enable the establishment of the similar safety profile of the test and reference&#xD;
      Fluticasone/Salmeterol combinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary variable will be the 12-hour average FEV1 [area under the FEV1 versus time curve divided by 12 (FEV1 AUC0-12/12)].</measure>
    <time_frame>0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)</time_frame>
    <description>To establish the therapeutic equivalence between the Fluticasone/Salmeterol combination administered with Elpenhaler® (Rolenium®) and the innovative one (Seretide Diskus®) in terms of their bronchodilator effect in lung function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The FEV1 values over time for the 12-hour observation period</measure>
    <time_frame>0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)</time_frame>
    <description>To compare the efficacy and safety profile of the two Fluticasone/Salmeterol formulations in patients with asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak FEV1</measure>
    <time_frame>0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)</time_frame>
    <description>To compare the effiacy and safety profile of the two Fluticasone/Salmeterol formulations in patients with asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak FEV1 maximum value</measure>
    <time_frame>same as FEV1</time_frame>
    <description>same as FEV1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Elpenhaler Active - Diskus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elpenhaler active - Diskus placebo</intervention_name>
    <description>randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.</description>
    <arm_group_label>Elpenhaler Active - Diskus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-65 years,&#xD;
&#xD;
          -  diagnosis of asthma of 6 months,&#xD;
&#xD;
          -  FEV1 ≥ 50% and ≤ 80% predicted,&#xD;
&#xD;
          -  reversibility of at least 12%,&#xD;
&#xD;
          -  stable asthma for at least 4 weeks,&#xD;
&#xD;
          -  inhaled steroids (ICS) at a stable dose within the previous 30 days,&#xD;
&#xD;
          -  PIF 30 - 90 lt/min and&#xD;
&#xD;
          -  informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of other pulmonary disease,&#xD;
&#xD;
          -  asthma exacerbation or respiratory infection within the previous 4 weeks,&#xD;
&#xD;
          -  hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral&#xD;
             steroid dose increase, within the previous 30 days,&#xD;
&#xD;
          -  heavy smokers,&#xD;
&#xD;
          -  change of asthma medication within the previous 4 weeks,&#xD;
&#xD;
          -  seasonal asthma alone,&#xD;
&#xD;
          -  history of severe heart disease,&#xD;
&#xD;
          -  pregnancy or lactation,&#xD;
&#xD;
          -  use of a β-blocker, of a NSAID or an antiallergic/antihistaminic medication within 2&#xD;
             weeks prior to screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Dindos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pneumology Surgery, Kojeticka 1021, 27711 Neratovicae</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pneumology surgery Vitezna 201/31</name>
      <address>
        <city>Karlovy Vary</city>
        <state>Drahovice</state>
        <zip>56001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology surgery Vojtesska 237</name>
      <address>
        <city>Kutna Hora</city>
        <state>Zizkov</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology and allergology surgery Voldusska 750</name>
      <address>
        <city>Nove Mesto</city>
        <zip>337 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology surgery Hostinskeho 1536</name>
      <address>
        <city>Prague</city>
        <zip>1536</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumology surgery Generala Janouska 902/17</name>
      <address>
        <city>Prague</city>
        <zip>19800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

